Table 2. Analysis of factors associated with EBV infection.
| Factors | HR | 95% CI | P value |
|---|---|---|---|
| First symptoms | 3.675 | 2.469–4.421 | 0.001 |
| Karyotype | 3.897 | 2.167–5.332 | 0.001 |
| Immunotyping | 2.812 | 1.098–3.876 | 0.014 |
| Clinical risk level | 3.228 | 2.385–5.623 | 0.003 |
| Secondary infections during chemotherapy | 3.140 | 2.187–4.876 | 0.005 |
| Lymphocyte subsets | |||
| CD3+ (%) | 2.165 | 1.256–3.338 | 0.041 |
| CD4+ (%) | 2.187 | 1.324–3.176 | 0.033 |
| CD8+ (%) | 2.365 | 1.564–3.338 | 0.029 |
| CD4+/CD8+ | 2.189 | 1.616–2.876 | 0.032 |
Assignment: first symptom (non-hepatosplenic lymph node enlargement =0, hepatosplenic lymph node enlargement =1), karyotype (normal =0, abnormal =1), immunophenotyping (T-cell type =0, B-cell type =1), clinical risk (low risk =0, intermediate risk =1, high risk =2), whether secondary infection occurred during chemotherapy (no =0, yes =1), entry of original value of lymphocyte subpopulation. EBV, Epstein-Barr virus; HR, hazard ratio; CI, confidence interval.